Q3 EPS Forecast for Aurora Cannabis Increased by Analyst

Aurora Cannabis Inc. (TSE:ACB) – Equities research analysts at Atb Cap Markets boosted their Q3 2026 EPS estimates for Aurora Cannabis in a research report issued to clients and investors on Wednesday, November 5th. Atb Cap Markets analyst F. Gomes now forecasts that the company will post earnings of $0.00 per share for the quarter, up from their prior estimate of ($0.05). The consensus estimate for Aurora Cannabis’ current full-year earnings is ($0.22) per share. Atb Cap Markets also issued estimates for Aurora Cannabis’ Q4 2026 earnings at $0.05 EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at ($0.18) EPS and FY2028 earnings at $0.10 EPS.

Aurora Cannabis Price Performance

Shares of Aurora Cannabis stock opened at C$6.38 on Monday. Aurora Cannabis has a twelve month low of C$4.95 and a twelve month high of C$9.90. The stock has a market capitalization of C$360.95 million, a price-to-earnings ratio of -6.25 and a beta of 1.01. The company has a quick ratio of 2.48, a current ratio of 3.42 and a debt-to-equity ratio of 18.72. The company has a 50-day simple moving average of C$7.23 and a two-hundred day simple moving average of C$6.93.

About Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.